Real-world experience of a cohort of previously untreated PI patients on SCIG
Monday, March 5, 2018
South Hall A2 (Convention Center)
Christopher Scalchunes, MPA, Rajiv Mallick, PhD, Jacob M. Romano, PharmD, RPh, BS, Tiffany S. Henderson, PHD
RATIONALE: To evaluate demographic, dosing and treatment satisfaction data from a large survey conducted by the Immune Deficiency Foundation (IDF) in a subset of treatment-naïve patients with primary immunodeficiency (PI), who initiated therapy on subcutaneous IG (SCIG).

METHODS: An online survey was sent to patients registered in the IDF database and was completed by the patients/caregivers between March 10–31, 2017. We report on infusion experience and satisfaction on SCIG therapy (based on the Treatment Satisfaction Questionnaire for Medication (TSQM) (effectiveness, side effects, convenience and global satisfaction) among the subset of treatment-naïve patients who started directly on SCIG.

RESULTS: Of 371 respondents on SCIG; 138 (37%) individuals reported not previously receiving IVIG. These patients tended to be female (85%), ≥30 years old (88%) and diagnosed with Common Variable Immune Deficiency (CVID) (88%). Compared to those who previously received IVIG, these respondents were more likely to be older at time of diagnosis (p<0.001), infuse somewhat less frequently (p<0.001), had a slightly shorter infusion time (p=0.05) and had fewer infusion sites (p<0.007). The mean total Treatment Satisfaction Questionnaire for Medication score (range 0–100) was 74 (SD 16). Overall, 85% of patients reported they were satisfied, very satisfied, or extremely satisfied with SCIG.

CONCLUSIONS: SCIG use in previously untreated PI patients is relatively common among a cohort of IDF members. The majority of these patients were satisfied to extremely satisfied with SCIG treatment. Furthermore, the relative efficiency of infusion characteristics among patients suggests the viability of initiating IG treatment directly on SCIG among some patients.